Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?

J Thorac Oncol. 2022 May;17(5):592-595. doi: 10.1016/j.jtho.2022.03.009.

Authors

Gavitt A Woodard¹, Christina Cho², Lieping Chen²

Affiliations

¹ Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, Yale University, New Haven, Connecticut. Electronic address: gavitt.woodard@yale.edu.
² Department of Immunobiology, Yale University School of Medicine, Yale University, New Haven, Connecticut.

PMID: 35465963
DOI: 10.1016/j.jtho.2022.03.009

No abstract available

Publication types

Editorial
Comment

MeSH terms

B7-H1 Antigen / genetics
Biomarkers
Biomarkers, Tumor / genetics
DNA Copy Number Variations*
Humans
Immunotherapy
Lung Neoplasms* / genetics
Lung Neoplasms* / therapy

Substances

B7-H1 Antigen
Biomarkers
Biomarkers, Tumor
CD274 protein, human